- Home
- JXJT vs NLSP Comparison
JXJT vs NLSP Comparison
Compare JXJT & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXJT
- NLSP
- Stock Information
- Founded
- JXJT 2012
- NLSP 2015
- Country
- JXJT China
- NLSP Switzerland
- Employees
- JXJT N/A
- NLSP N/A
- Industry
- JXJT Apparel
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- JXJT Consumer Staples
- NLSP Health Care
- Exchange
- JXJT Nasdaq
- NLSP Nasdaq
- Market Cap
- JXJT 11.5M
- NLSP 243.8M
- IPO Year
- JXJT 2012
- NLSP 2021
- Fundamental
- Price
- JXJT $1.57
- NLSP $4.96
- Analyst Decision
- JXJT
- NLSP
- Analyst Count
- JXJT 0
- NLSP 0
- Target Price
- JXJT N/A
- NLSP N/A
- AVG Volume (30 Days)
- JXJT 36.7K
- NLSP 34.6K
- Earning Date
- JXJT 11-01-2024
- NLSP 11-01-2024
- Dividend Yield
- JXJT N/A
- NLSP N/A
- EPS Growth
- JXJT N/A
- NLSP N/A
- EPS
- JXJT 0.48
- NLSP N/A
- Revenue
- JXJT $31,840,588.00
- NLSP N/A
- Revenue This Year
- JXJT N/A
- NLSP N/A
- Revenue Next Year
- JXJT N/A
- NLSP N/A
- P/E Ratio
- JXJT $3.40
- NLSP N/A
- Revenue Growth
- JXJT N/A
- NLSP N/A
- 52 Week Low
- JXJT $1.04
- NLSP $4.08
- 52 Week High
- JXJT $8.51
- NLSP $29.68
- Technical
- Relative Strength Index (RSI)
- JXJT 38.73
- NLSP 46.37
- Support Level
- JXJT $1.40
- NLSP $4.52
- Resistance Level
- JXJT $1.75
- NLSP $5.64
- Average True Range (ATR)
- JXJT 0.14
- NLSP 0.48
- MACD
- JXJT -0.04
- NLSP 0.07
- Stochastic Oscillator
- JXJT 32.08
- NLSP 55.44
About JXJT JX Luxventure Limited
JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.